Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.

2.

Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies.

Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA, Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ; Australian Prostate Cancer BioResource.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1755-65. doi: 10.1158/1055-9965.EPI-10-0059.

3.

Standard preanalytical coding for biospecimens: defining the sample PREanalytical code.

Betsou F, Lehmann S, Ashton G, Barnes M, Benson EE, Coppola D, DeSouza Y, Eliason J, Glazer B, Guadagni F, Harding K, Horsfall DJ, Kleeberger C, Nanni U, Prasad A, Shea K, Skubitz A, Somiari S, Gunter E; International Society for Biological and Environmental Repositories (ISBER) Working Group on Biospecimen Science.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1004-11. doi: 10.1158/1055-9965.EPI-09-1268. Epub 2010 Mar 23.

4.

Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R.

Oncol Rep. 2010 Apr;23(4):1045-52.

PMID:
20204290
5.

Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.

Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, Marshall VR, Horsfall DJ.

Prostate. 2009 May 15;69(7):761-9. doi: 10.1002/pros.20926.

PMID:
19189303
6.

The biological role and regulation of versican levels in cancer.

Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ.

Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45. doi: 10.1007/s10555-009-9182-y. Review.

PMID:
19160015
7.

Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse.

Sakko AJ, Butler MS, Byers S, Reinboth BJ, Stahl J, Kench JG, Horvath LG, Sutherland RL, Stricker PD, Henshall SM, Marshall VR, Tilley WD, Horsfall DJ, Ricciardelli C.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2488-97. doi: 10.1158/1055-9965.EPI-08-0204.

8.

Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.

Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD.

Prostate. 2008 Jun 1;68(8):830-8. doi: 10.1002/pros.20747.

PMID:
18324648
9.

Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility.

Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ.

J Biol Chem. 2007 Apr 6;282(14):10814-25. Epub 2007 Feb 9.

10.

Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation.

Sakko AJ, Ricciardelli C, Mayne K, Dours-Zimmermann MT, Zimmermann DR, Neufing P, Tilley WD, Marshall VR, Horsfall DJ.

Prostate. 2007 Feb 15;67(3):288-300.

PMID:
17192879
11.

Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.

Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD.

Cancer Res. 2005 Sep 15;65(18):8487-96.

12.

Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.

Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD.

Prostate. 2005 Apr 1;63(1):19-28.

PMID:
15378523
13.

Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer.

Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ.

Clin Cancer Res. 2004 Apr 1;10(7):2491-8.

14.

Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.

Hall RE, Horsfall DJ, Stahl J, Vivekanandan S, Ricciardelli C, Stapleton AM, Scardino PT, Neufing P, Tilley WD.

Prostate. 2004 Feb 1;58(2):103-8.

PMID:
14716735
15.

Modulation of prostate cancer cell attachment to matrix by versican.

Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, Tilley WD, Horsfall DJ.

Cancer Res. 2003 Aug 15;63(16):4786-91.

16.

Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues.

Neufing PJ, Kalionis B, Horsfall DJ, Ricciardelli C, Stahl J, Vivekanandan S, Raymond W, Tilley WD.

Anticancer Res. 2003 Mar-Apr;23(2B):1479-88.

PMID:
12820413
17.

Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer.

Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ.

Clin Cancer Res. 2002 Apr;8(4):1054-60.

18.

A potential autocrine role for vascular endothelial growth factor in prostate cancer.

Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD.

Cancer Res. 2002 Feb 1;62(3):854-9. Erratum in: Cancer Res 2002 Apr 1;62(7):2200.

19.

Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1.

Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ.

Cancer Res. 2001 Feb 1;61(3):926-30.

20.

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.

Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD.

Mol Endocrinol. 2001 Jan;15(1):46-56.

PMID:
11145738
21.

Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.

Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD.

Mol Cell Endocrinol. 1999 Aug 20;154(1-2):11-20.

PMID:
10509795
22.

A simple index using video image analysis to predict disease outcome in primary breast cancer.

Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ.

Int J Cancer. 1999 Jun 21;84(3):203-8.

23.

Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.

Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ.

Cancer Res. 1999 May 15;59(10):2324-8.

24.

Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers.

Zhang SX, Bentel JM, Ricciardelli C, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD.

J Urol. 1998 Feb;159(2):548-54.

PMID:
9649289
25.

Tumor microvascularity has no independent prognostic significance for breast cancer.

Mayers MM, Seshadri R, Raymond W, McCaul K, Horsfall DJ.

Pathology. 1998 May;30(2):105-10.

PMID:
9643487
26.

Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.

Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Horsfall DJ.

Clin Cancer Res. 1998 Apr;4(4):963-71.

27.

A simple index to predict prognosis independent of axillary node information in breast cancer.

Seshadri R, Horsfall DJ, McCaul K, Leong AS.

Aust N Z J Surg. 1997 Nov;67(11):765-70.

PMID:
9396991
28.

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.

Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL.

Oncogene. 1997 Sep 25;15(13):1617-23.

29.

Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.

Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Tilley WD, Skinner JM, Horsfall DJ.

Clin Cancer Res. 1997 Jun;3(6):983-92.

30.

Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer.

Hall RE, Aspinall JO, Horsfall DJ, Birrell SN, Bentel JM, Sutherland RL, Tilley WD.

Br J Cancer. 1996 Oct;74(8):1175-80.

31.

Vimentin expression is not associated with poor prognosis in breast cancer.

Seshadri R, Raymond WA, Leong AS, Horsfall DJ, McCaul K.

Int J Cancer. 1996 Jul 29;67(3):353-6.

32.
33.

Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis.

Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ.

Int J Cancer. 1996 Apr 22;69(2):135-41. Erratum in: Int J Cancer 1996 Aug 22;69(4):354.

34.

Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer.

Seshadri R, McLeay WR, Horsfall DJ, McCaul K.

Int J Cancer. 1996 Feb 20;69(1):23-7.

35.

Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues.

Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD.

J Urol. 1995 Aug;154(2 Pt 1):622-8.

PMID:
7541868
36.

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.

Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD.

J Clin Oncol. 1995 Jul;13(7):1572-7.

PMID:
7602345
37.

Androgens induce divergent proliferative responses in human breast cancer cell lines.

Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD.

J Steroid Biochem Mol Biol. 1995 May;52(5):459-67.

PMID:
7748811
38.

Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3.

Tilley WD, Bentel JM, Aspinall JO, Hall RE, Horsfall DJ.

Steroids. 1995 Jan;60(1):180-6.

PMID:
7792809
39.

Glycosaminoglycans of guinea pig prostate fibromuscular stroma: influence of estrogen and androgen on levels and location of chondroitin sulfate.

Horsfall DJ, Mayne K, Skinner JM, Saccone GT, Marshall VR, Tilley WD.

Prostate. 1994 Dec;25(6):320-32.

PMID:
7997436
40.

Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis.

Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM.

Cancer Res. 1994 Aug 1;54(15):4096-102.

41.

Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer.

Miller J, Horsfall DJ, Skinner JM, Rao DM, Leong AS, Marshall VR.

Prostate. 1994 Jun;24(6):306-12.

PMID:
7516069
42.

Age-related changes in guinea pig prostatic stroma.

Horsfall DJ, Mayne K, Ricciardelli C, Rao M, Skinner JM, Henderson DW, Marshall VR, Tilley WD.

Lab Invest. 1994 May;70(5):753-63.

PMID:
8196369
43.
44.

The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group.

Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkins H, Hahnel R.

Int J Cancer. 1994 Jan 2;56(1):61-5.

PMID:
8262679
45.

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P.

J Clin Oncol. 1993 Oct;11(10):1936-42.

PMID:
8105035
46.

Epidermal growth factor receptor in breast cancer: storage conditions affecting measurement, and relationship to steroid receptors.

McLeay WR, Horsfall DJ, Seshadri R, Morrison DA, Saccone GT.

Breast Cancer Res Treat. 1992;22(2):141-51.

PMID:
1391979
47.

Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF.

Gill PG, Tilley WD, De Young NJ, Lensink IL, Dixon PD, Horsfall DJ.

Breast Cancer Res Treat. 1991 Dec;20(1):53-62.

PMID:
1813069
48.

The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma.

Miller J, Horsfall DJ, Marshall VR, Rao DM, Leong SY.

J Urol. 1991 Jun;145(6):1192-6.

PMID:
2033691
49.

Steroid hormone and epidermal growth factor receptors in meningiomas.

Horsfall DJ, Goldsmith KG, Ricciardelli C, Skinner JM, Tilley WD, Marshall VR.

Aust N Z J Surg. 1989 Nov;59(11):881-8.

PMID:
2818349
50.

Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate.

Ricciardelli C, Horsfall DJ, Skinner JM, Henderson DW, Marshall VR, Tilley WD.

In Vitro Cell Dev Biol. 1989 Nov;25(11):1016-24.

PMID:
2592295

Supplemental Content

Loading ...
Support Center